BIOMAT Database Logo BIOMAT Database Logo

Dual apoC-II mimetic and apoC-III antagonist for hypertriglyceridaemia. 2020

Karina Huynh
Nature Reviews Cardiology, . nrcardio@nature.com.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride
D015228 Hypertriglyceridemia A condition of elevated levels of TRIGLYCERIDES in the blood. Hypertriglyceridemias
D053304 Apolipoprotein C-II A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS. It contains a cofactor for LIPOPROTEIN LIPASE and activates several triacylglycerol lipases. The association of Apo C-II with plasma CHYLOMICRONS; VLDL, and HIGH-DENSITY LIPOPROTEINS is reversible and changes rapidly as a function of triglyceride metabolism. Clinically, Apo C-II deficiency is similar to lipoprotein lipase deficiency (HYPERLIPOPROTEINEMIA TYPE I) and is therefore called hyperlipoproteinemia type IB. Apo C-II,ApoC2,Apolipoprotein C-2,Apolipoprotein CII,Apoprotein C-II,Apo C II,Apolipoprotein C 2,Apolipoprotein C II,Apoprotein C II
D053305 Apolipoprotein C-III A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). Apo C-III,Apo C-III-2,ApoC-III,Apolipoprotein C-III-0,Apolipoprotein C-III-1,Apolipoprotein CIII,Sialyl Apo C-III,Sialyl Apolipoprotein C-III,Apo C III,Apo C III 2,Apo C-III, Sialyl,ApoC III,Apolipoprotein C III,Apolipoprotein C III 0,Apolipoprotein C III 1,Apolipoprotein C-III, Sialyl,Sialyl Apo C III,Sialyl Apolipoprotein C III

Related Publications

Karina Huynh
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
January 2020, Science translational medicine,
Karina Huynh
Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.
February 2016, The Journal of pharmacology and experimental therapeutics,
Karina Huynh
Severe hypertriglyceridaemia in Type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency.
November 2000, Diabetologia,
Karina Huynh
Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
August 2016, European journal of clinical investigation,
Karina Huynh
Quantification of apoC-II and apoC-III of human very low density lipoproteins by analytical isoelectric focusing.
November 1978, Journal of lipid research,
Karina Huynh
[The ratios of apoC-III/apoC-II in normal full-term maternal bloods and their umbilical cord bloods].
January 2001, Rinsho byori. The Japanese journal of clinical pathology,
Karina Huynh
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.
October 2003, Journal of lipid research,
Karina Huynh
Analysis of the apoC-II gene in apoC-II deficient patients.
October 1984, Biochemical and biophysical research communications,
Karina Huynh
Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
April 2012, Journal of lipid research,
Karina Huynh
Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia.
March 1988, Journal of lipid research,
Copied contents to your clipboard!